Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.92 ^USD	-0.11%		-15.61%	+12.06%

Apr. 24	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	MT
Apr. 24	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	MT

Centessa Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 04:23 pm EST

Centessa Pharmaceuticals plc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 38.65 million compared to USD 53.88 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.57 a year ago.
For the nine months, net loss was USD 114.25 million compared to USD 173.03 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 1.86 a year ago.

Latest news about Centessa Pharmaceuticals plc

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	Apr. 24	MT
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	Apr. 24	MT
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering	Apr. 23	MT
Centessa Pharmaceutical Gets FDA's Approval to Begin Phase 1 Trial of Narcolepsy Drug Candidate	Apr. 22	MT
Centessa Pharmaceuticals plc Announces Open IND for ORX750	Apr. 22	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing	Mar. 26	MT
ADRs End Lower, WISekey International Holding Ltd. Declines 17.3%	Jan. 17	DJ
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia	Dec. 10	CI
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	Nov. 27	MT
Anaptysbio, Inc. Enters into License Agreement with Centessa Pharmaceuticals (UK) Limited	Nov. 27	CI
Centessa Pharmaceuticals' Q3 Loss Narrows	Nov. 13	MT
Centessa Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors	23-10-31	CI
Morgan Stanley Upgrades Centessa Pharmaceuticals to Equalweight From Underweight, Doubles Price Target to $8 From $4 on 'Encouraging' Preclinical Data on Narcolepsy Treatment Candidate	23-10-26	MT
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders	23-10-25	CI
Centessa Pharmaceuticals plc Announces Executive Appointments	23-10-04	CI
ADRs Slump, The9 Ltd. Declines 28.9%	23-10-02	DJ
Centessa Pharmaceuticals Insider Sold Shares Worth $235,688, According to a Recent SEC Filing	23-09-22	MT
Transcript : Centessa Pharmaceuticals plc Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:15 PM	23-09-12
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc	23-08-24	CI
Guggenheim Adjusts Price Target on Centessa Pharmaceuticals to $10 From $9, Maintains Buy Rating	23-08-15	MT
Goldman Sachs Adjusts Price Target on Centessa Pharmaceuticals to $5 From $4.50, Maintains Neutral Rating	23-08-15	MT
Centessa Pharmaceuticals plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI

Chart Centessa Pharmaceuticals plc

Duration

Period

More charts

Company Profile

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.92 USD

Average target price

13.6 USD

Spread / Average Target

+52.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CENTESSA PHARMACEUTICALS PLC	+12.06%	991M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research